BACKGROUND: A proportion of patients with chronic obstructive pulmonary disease (COPD) may progress rapidly to small cell lung cancer (SCLC). As the forced expiratory volume in 1 second (FEV1)/forced volume vital capacity (FVC) ratio is usually impaired in patients with COPD, and given that the FEV1 and FVC are not necessarily related to lung cancer development, we performed this study to test our hypothesis that the FEV1/FVC ratio predicts survival of patients with limited-stage (LS)-SCLC. METHODS: We assessed 74 patients with LS-SCLC treated with chemoradiotherapy. The patients were divided into two FEV1/FVC ratio groups: <0.74 (n=24) and ≥0.74 (n=50). RESULTS: The 3-year overall survival (OS) and 3-year progression-free survival (PFS) rates were significantly lower in patients with FEV1/FVC <0.74 than in those with FEV1/FVC ≥0.74 group (35.4% vs. 61.2%, P=0.0033; and 11.7% vs. 51.8%, P=0.0072, respectively). On multivariate analysis, the low FEV1/FVC group was independently associated with OS and PFS [hazard ratio (HR) (95% confidence interval): 2.15 (0.99-4.63), P=0.052; and 2.13 (1.04-4.39), P=0.039, respectively]. CONCLUSIONS: Pretreatment FEV1/FVC ratio appears to be a potential prognostic factor for patients with LS-SCLC.
BACKGROUND: A proportion of patients with chronic obstructive pulmonary disease (COPD) may progress rapidly to small cell lung cancer (SCLC). As the forced expiratory volume in 1 second (FEV1)/forced volume vital capacity (FVC) ratio is usually impaired in patients with COPD, and given that the FEV1 and FVC are not necessarily related to lung cancer development, we performed this study to test our hypothesis that the FEV1/FVC ratio predicts survival of patients with limited-stage (LS)-SCLC. METHODS: We assessed 74 patients with LS-SCLC treated with chemoradiotherapy. The patients were divided into two FEV1/FVC ratio groups: <0.74 (n=24) and ≥0.74 (n=50). RESULTS: The 3-year overall survival (OS) and 3-year progression-free survival (PFS) rates were significantly lower in patients with FEV1/FVC <0.74 than in those with FEV1/FVC ≥0.74 group (35.4% vs. 61.2%, P=0.0033; and 11.7% vs. 51.8%, P=0.0072, respectively). On multivariate analysis, the low FEV1/FVC group was independently associated with OS and PFS [hazard ratio (HR) (95% confidence interval): 2.15 (0.99-4.63), P=0.052; and 2.13 (1.04-4.39), P=0.039, respectively]. CONCLUSIONS: Pretreatment FEV1/FVC ratio appears to be a potential prognostic factor for patients with LS-SCLC.
Entities:
Keywords:
Forced expiratory volume; forced volume vital capacity (FVC); prognosis; small cell lung cancer (SCLC)
Authors: Mark P Purdue; Laura Gold; Bengt Järvholm; Michael C R Alavanja; Mary H Ward; Roel Vermeulen Journal: Thorax Date: 2006-08-23 Impact factor: 9.139
Authors: Graeme J K Guthrie; Kellie A Charles; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan; Stephen J Clarke Journal: Crit Rev Oncol Hematol Date: 2013-04-17 Impact factor: 6.312
Authors: A Papi; G Casoni; G Caramori; I Guzzinati; P Boschetto; F Ravenna; N Calia; S Petruzzelli; L Corbetta; G Cavallesco; E Forini; M Saetta; A Ciaccia; L M Fabbri Journal: Thorax Date: 2004-08 Impact factor: 9.139
Authors: Ane Johannessen; Sverre Lehmann; Ernst R Omenaas; Geir Egil Eide; Per S Bakke; Amund Gulsvik Journal: Am J Respir Crit Care Med Date: 2006-03-23 Impact factor: 21.405
Authors: Claus F Vogelmeier; Gerard J Criner; Fernando J Martínez; Antonio Anzueto; Peter J Barnes; Jean Bourbeau; Bartolome R Celli; Rongchang Chen; Marc Decramer; Leonardo M Fabbri; Peter Frith; David M G Halpin; M Victorina López Varela; Masaharu Nishimura; Nicolás Roche; Roberto Rodríguez-Roisin; Don D Sin; Dave Singh; Robert Stockley; Jørgen Vestbo; Jadwiga A Wedzicha; Alvar Agustí Journal: Arch Bronconeumol Date: 2017-03-06 Impact factor: 4.872
Authors: I Re Heo; Ho Cheol Kim; Seung Jun Lee; Jung-Wan Yoo; Sunmi Ju; Yi Yeong Jeong; Jong Deog Lee; Yu Ji Cho; Jong Hwan Jeong; Manbong Heo; Seung Woo Jung; Tae Hoon Kim Journal: Thorac Cancer Date: 2021-08-01 Impact factor: 3.500